SG11201809297UA - Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients - Google Patents
Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patientsInfo
- Publication number
- SG11201809297UA SG11201809297UA SG11201809297UA SG11201809297UA SG11201809297UA SG 11201809297U A SG11201809297U A SG 11201809297UA SG 11201809297U A SG11201809297U A SG 11201809297UA SG 11201809297U A SG11201809297U A SG 11201809297UA SG 11201809297U A SG11201809297U A SG 11201809297UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- idalopirdine
- pct
- acetylcholinesterase inhibitor
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600248 | 2016-04-26 | ||
| PCT/EP2017/059739 WO2017186686A1 (en) | 2016-04-26 | 2017-04-25 | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809297UA true SG11201809297UA (en) | 2018-11-29 |
Family
ID=58632402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809297UA SG11201809297UA (en) | 2016-04-26 | 2017-04-25 | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10383849B2 (pt) |
| EP (1) | EP3448430B1 (pt) |
| JP (1) | JP6992004B2 (pt) |
| KR (1) | KR102473545B1 (pt) |
| CN (1) | CN109069650A (pt) |
| AU (1) | AU2017256623B2 (pt) |
| BR (1) | BR112017026928B1 (pt) |
| CA (1) | CA3020557C (pt) |
| CL (1) | CL2018003013A1 (pt) |
| CY (1) | CY1126138T1 (pt) |
| DK (1) | DK3448430T3 (pt) |
| ES (1) | ES2949288T3 (pt) |
| FI (1) | FI3448430T3 (pt) |
| HR (1) | HRP20230693T8 (pt) |
| HU (1) | HUE062626T2 (pt) |
| IL (1) | IL262546B (pt) |
| LT (1) | LT3448430T (pt) |
| MX (1) | MX2018013031A (pt) |
| PL (1) | PL3448430T3 (pt) |
| PT (1) | PT3448430T (pt) |
| RS (1) | RS64307B1 (pt) |
| RU (1) | RU2742173C2 (pt) |
| SG (1) | SG11201809297UA (pt) |
| SI (1) | SI3448430T1 (pt) |
| TW (1) | TW201806621A (pt) |
| WO (1) | WO2017186686A1 (pt) |
| ZA (1) | ZA201806864B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201909895UA (en) * | 2017-05-24 | 2019-11-28 | H Lundbeck As | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
| JP2021515801A (ja) * | 2017-12-22 | 2021-06-24 | ニューロセア，エルエルシー | 神経変性疾患における転倒および転倒頻度に関連する処置のための組成物および方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| DK1379239T3 (da) * | 2001-03-29 | 2008-01-07 | Lilly Co Eli | N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren |
| WO2006107860A2 (en) * | 2005-04-04 | 2006-10-12 | Eisai Co., Ltd. | Dihydropyridine compounds and compositions for headaches |
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| US20100120747A1 (en) * | 2006-06-23 | 2010-05-13 | Laboratorios Del Dr. Esteve, S.A. | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
| US9084742B2 (en) * | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| RU2393158C1 (ru) * | 2008-10-06 | 2010-06-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
-
2017
- 2017-04-25 CA CA3020557A patent/CA3020557C/en active Active
- 2017-04-25 FI FIEP17719255.6T patent/FI3448430T3/fi active
- 2017-04-25 SG SG11201809297UA patent/SG11201809297UA/en unknown
- 2017-04-25 CN CN201780025728.1A patent/CN109069650A/zh active Pending
- 2017-04-25 BR BR112017026928-7A patent/BR112017026928B1/pt active IP Right Grant
- 2017-04-25 HU HUE17719255A patent/HUE062626T2/hu unknown
- 2017-04-25 RS RS20230489A patent/RS64307B1/sr unknown
- 2017-04-25 SI SI201731371T patent/SI3448430T1/sl unknown
- 2017-04-25 DK DK17719255.6T patent/DK3448430T3/da active
- 2017-04-25 PT PT177192556T patent/PT3448430T/pt unknown
- 2017-04-25 RU RU2018135846A patent/RU2742173C2/ru active
- 2017-04-25 HR HRP20230693TT patent/HRP20230693T8/hr unknown
- 2017-04-25 ES ES17719255T patent/ES2949288T3/es active Active
- 2017-04-25 AU AU2017256623A patent/AU2017256623B2/en active Active
- 2017-04-25 KR KR1020187030934A patent/KR102473545B1/ko active IP Right Grant
- 2017-04-25 EP EP17719255.6A patent/EP3448430B1/en active Active
- 2017-04-25 US US15/496,159 patent/US10383849B2/en active Active
- 2017-04-25 MX MX2018013031A patent/MX2018013031A/es unknown
- 2017-04-25 LT LTEPPCT/EP2017/059739T patent/LT3448430T/lt unknown
- 2017-04-25 TW TW106113760A patent/TW201806621A/zh unknown
- 2017-04-25 WO PCT/EP2017/059739 patent/WO2017186686A1/en active Application Filing
- 2017-04-25 JP JP2018555748A patent/JP6992004B2/ja active Active
- 2017-04-25 PL PL17719255.6T patent/PL3448430T3/pl unknown
-
2018
- 2018-10-15 ZA ZA2018/06864A patent/ZA201806864B/en unknown
- 2018-10-24 IL IL262546A patent/IL262546B/en unknown
- 2018-10-24 CL CL2018003013A patent/CL2018003013A1/es unknown
-
2023
- 2023-08-04 CY CY20231100395T patent/CY1126138T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201805061YA (en) | Crystalline form of gemcitabine | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11202000494UA (en) | Drug delivery composition |